THE ONSET OF PSORIASIS DURING THE TREATMENT OF INFLAMMATORY BOWEL DISEASES WITH INFlixIMAB: should biological therapy be suspended?

Rafael DENADAI, Fábio Vieira TEIXEIRA and Rogério SAAD-HOSSNE

ABSTRACT – Context - Several paradoxical cases of infliximab-induced or-exacerbated psoriatic lesions have been described in the recent years. There is disagreement regarding the need to discontinue infliximab in order to achieve the resolution of these adverse cutaneous reactions specifically in inflammatory bowel disease (IBD) patients. Objective - To systematically review the literature to collect information on IBD patients that showed this adverse cutaneous reaction, focusing mainly on the therapeutic approach. Methods - A systematic literature review was performed utilizing Medline, Embase, SciELO and Lilacs databases. Published studies were identified, reviewed and the data were extracted. Results - Thirty-four studies (69 IBD patients) met inclusion criteria for review. There was inconsistency in reporting of some clinical and therapeutic aspects. Most patients included had Crohn’s disease (89.86%), was female (47.83%), had an average age of 27.11 years, and no reported history of psoriasis (84.05%). The patients developed primarily plaque-type psoriasis (40.58%). There was complete remission of psoriatic lesions in 86.96% of IBD patients, existing differences in the therapeutic approaches; cessation of infliximab therapy led to resolution in 47.83% of cases and 43.48% of patients were able to continue infliximab therapy. Conclusion - As increasing numbers of IBD patients with psoriasis induced or exacerbated by infliximab, physicians should be aware of its clinical manifestations so that appropriate diagnosis and treatment are properly established. The decision whether to continue or discontinue infliximab should be individualized.

INTRODUCTION

Infliximab is a chimeric IgG1 monoclonal antibody (75% human and 25% murine) that inhibits the tumor necrosis factor-alpha (anti-TNF-α). It has been efficient in the treatment of inflammatory bowel diseases (IBD) for more than a decade (20); however, since 2004, the number of paradoxical cases of psoriasis induced or exacerbated by infliximab described in IBD patients have increased (6, 10, 14, 32, 37), since TNF-α inhibition determines therapeutic benefits in psoriasis (4).

With this regard, there is disagreement in the literature as to the need to suspend biological therapy in order to achieve complete resolution of these cutaneous lesions (psoriasis), specifically in IBD patients. Some authors (6, 14) agree to its withdrawal while others (10, 32, 37) report that the biological must be maintained.

Due to risk for IBD deterioration after suspension of the TNF-α inhibitory molecule, the authors of the present study aimed at presenting a systematic literature review on this intriguing phenomenon (psoriasis induced or exacerbated by infliximab) specifically in patients with IBD, mainly focusing on its therapeutic aspects.

METHODS

Search strategy

A systematic literature review was performed using the Medline (PubMed), Embase, SciELO and Lilacs databases from January 2004 to September 2011 so as to collect all relevant articles in English specifically addressing IBD patients who developed psoriasis after receiving infliximab by searching up the following terms “anti-TNF-α”, “biological”, “Crohn” “inflammatory bowel disease”, “infliximab”, “TNF inhibitor”, “tumor necrosis factor alpha inhibitor” and “ulcerative colitis” combined with terms “adverse event”, “exacerbated,” “guttate”, “new-onset”, “plaque”, “pustular” and “psoriasis”.

Research performed at Division of Coloproctology, Department of Surgery, School of Medical Sciences, State University of São Paulo (UNESP), Botucatu, SP, Brazil.

Sources of funding: none.

Conflict of interest: The authors declare that they have no conflict of interest.

Division of Coloproctology, Department of Surgery, Botucatu Medical School, University of the State of São Paulo (UNESP), Botucatu, SP, Brazil.

Correspondence: Dr. Rafael Denadai - Paula Fabiana Tudeia, 161 – Esmeralda – 17516-707 - Marília, SP, Brazil. E-mail: silva.rdp@hotmail.com

ARG GASTROENTEROL v. 49 – no. 2 – abr./jun. 2012
Study selection, data extraction and analysis

The identified studies were selected for analysis based on their titles and abstracts whenever they were available. The studies that did not contain specific information on IBD patients who developed psoriasis during infliximab therapy were excluded. Each study included was individually reviewed in order to collect data concerning age, gender, personal and family history of psoriasis, biological medication administered, clinical latency, cutaneous lesion type, cutaneous biopsy performance, therapeutic approaches and outcomes. Two authors were responsible for data extraction independently and disagreements were resolved by consensus. Considering that such information does not provide sufficient data evidence or meta-analysis data, a critical and descriptive analysis was performed.

RESULTS

In the evaluated period and based on the previously described reviewing methodology, 69 patients with psoriasis induced or exacerbated during IBD therapy were found(1-3, 5, 7-9, 11, 12, 15-18, 21-23, 25-31, 33-36, 38-44). The cases were described in 34 publications (33 peer-reviewed and one abstract of congress). Some information, such as gender, age, latency time between infliximab administration and the onset of psoriasis, cutaneous biopsy performance, therapeutic approach and clinical outcomes, was not described in all studies. A summary with the main demographic and clinical characteristics of the 69 IBD patients found is included in Table 1.

Demographics

Most of the patients who developed psoriasis received infliximab in order to control Crohn's disease (89.86%). They were females (47.83%), with a mean age of 27.11 years and did not report a personal and/or family history of psoriasis (84.05%). In three patients, pre-existing psoriasis was exacerbated(25, 26), and in three others, there was a positive family history of psoriasis(12, 29, 30).

TABLE 1. Summary of data on 69 inflammatory bowel disease patients who developed psoriasis after administration of infliximab published until September 2011

| Characteristics                          | Patients (n = 69) |
|------------------------------------------|------------------|
| **Primary disease, n (%)**               |                  |
| CD                                       | 62 (89.86)       |
| UC                                       | 5.0 (7.25)       |
| IBD *                                    | 2.0 (2.89)       |
| **Gender, n (%)**                        |                  |
| Female                                   | 33 (47.83)       |
| Male                                     | 32 (46.38)       |
| Unknown                                  | 4.0 (5.80)       |
| **Median age (years)**                   | 27.11 (8–54)     |
| Unknown, n (%)                           | 6.0 (8.70)       |
| **Previous history of PS, n (%)**        |                  |
| No (de novo or induced PS)               | 58 (84.05)       |
| Personal (exacerbated pre-existing PS)   | 3.0 (4.35)       |
| Familiar                                 | 4.0 (5.80)       |
| Unknown                                  | 4.0 (5.80)       |
| Clinical latency (months)                | 14.15 (0.5–42)   |
| Unknown ***, n (%)                       | 3.0 (4.35)       |
| **Type of skin lesion, n (%)**           |                  |
| Plaque-type PS                           | 28 (40.58)       |
| Pustular-type PS                         | 6.0 (8.70)       |
| Psoriasiform lesions                     | 5.0 (7.25)       |
| More than one form of PS                 | 6.0 (8.70)       |
| Guttate-type PS                          | 2.0 (2.90)       |
| Diffuse-type PS                          | 2.0 (2.90)       |
| Other                                    | 6.0 (8.70)       |
| Unknown                                  | 14 (20.29)       |

UC = ulcerative colitis; CD = Crohn disease; IBD = inflammatory bowel disease; PS = Psoriasis; * = Ulcerative colitis or Crohn disease; ** = Some studies have reported only the number of doses administered
Biological therapy

The mean time of clinical latency between the beginning of infliximab infusions and the onset of psoriasis was of 14.15 months. In addition to infliximab, some patients also developed psoriasis with the administration of adalimumab(5, 8, 17), etanercept (used for associated spondyloarthritis)(35), and infliximab replacement for another inhibitory molecule (such as IFN-α producers) are capable of inducing psoriasis(6, 18, 22). Since such plasmocytoid dendritic cells are usually downregulated by TNF-α, its inhibition by the biological may determine increased and uncontrolled IFN-α production and consequently induce or exacerbate psoriasis(6, 18, 22).

Clinical presentation

Clinical presentation varied among the IBD patients who developed psoriasis during infliximab infusions, and there was predominance of plaque-type psoriasis (40.58%), followed by the pustular type (8.70%), and psoriasisiform eruptions (7.25%).

Cutaneous biopsy

In this review, the histopathological findings (lymphocytic infiltrate in the epidermis, epithelial hyperplasia with acanthosis and hyperkeratosis, parakeratosis, and dilated capillaries) in the 42 IBD patients submitted to cutaneous biopsy confirmed the clinical hypotheses of psoriasis(1, 2, 7, 34, 39, 41, 44) in other studies(6, 7, 14, 44) most cases were described in patients treated with infliximab (the object of this study). However, as there are cases involving different TNF-α inhibitors (infliximab, adalimumab, etanercept, and certolizumab)(6, 7, 10, 14, 44), such side effect has been described as a reaction to the pharmacological class, and not specifically to one drug(6, 15, 18). The pathogenesis of this paradoxical phenomenon (psoriasis subsequent to infliximab therapy) is still not completely known, and it is believed that plasmocytoid dendritic cells (natural IFN-α producers) are capable of inducing psoriasis through IFN-α production(6, 18, 22). Since such plasmocytoid cells are usually downregulated by TNF-α, its inhibition by the biological may determine increased and uncontrolled IFN-α production and consequently induce or exacerbate psoriasis(6, 18, 22).

Although in some patients, the diagnosis of psoriasis induced or exacerbated by infliximab was based only on the clinical aspect of cutaneous lesions, it has been described that patients must be evaluated by a dermatologist with the purpose to confirm the psoriasis hypothesis (correlating clinical manifestations with histopathological findings(35)) and discard similar cutaneous diseases (e.g., acute exanthematous pustulosis) and other psoriasis-triggering factors (e.g., infections and other medications)(6, 7).

In the literature, various therapeutic approaches have been described for the cases of psoriasis subsequent to infliximab administration. Regardless of the base disease, anti-TNF-α interruption or replacement culminated in the resolution of cutaneous lesions in 24% and 15% of cases, respectively(6, 8). In other reviews(6, 14), such strategy ( interruption or replacement of the inhibitory molecule) has been more successful especially in IBD patients; resolution of cutaneous lesions after anti-TNF-α discontinuation was observed in 46%-88% of cases(6, 14), while only 34% of patients showed resolution of cutaneous lesions without suspension of the biological(6). However, these data must be cautiously interpreted because anti-TNF-α withdrawal can determine the aggravation of intestinal manifestations(3, 9, 17, 31, 38, 40).

Based on the present review(6, 7, 14, 33, 34, 38, 39, 40, 44), the IBD patients developing psoriasis during infliximab therapy must be treated by the conventional psoriasis approach (topical corticosteroids, phototherapy, vitamin-D analogs, methotrexate and/or cyclosporine) without the need to suspend infliximab. The discontinuation of infliximab infusions must be considered, especially in generalized, recalcitrant cases of psoriasis with important impact on quality of life. After the resolution of skin lesions, the reintroduction of biological therapy must be considered. In cases where it is necessary to suspend the biological, but IBD is aggressive, and infliximab withdrawal may lead to clinical deterioration, the adoption of alternative therapeutic forms (e.g., antibiotics, mesalazine, or azathioprine) for IBD control, or infliximab replacement for another inhibitory molecule must be considered. Although the administration of systemic corticosteroids has been used in some cases(2, 23, 41, 44), its introduction must be carefully analyzed due to the existing risk for psoriasis rebound(19).

In the majority of patients (86.66%) showed complete remission of cutaneous lesions; however, therapeutic approaches varied (Table 2). Topical corticosteroids were the main anti-psoriatic therapy used (73.91%). Infliximab was suspended, which resulted in psoriasis resolution in 47.83% of cases while cutaneous lesions receded even with subsequent infliximab infusions in 43.48% of cases.
CONCLUSIONS

As the number of IBD patients showing psoriasis after receiving infliximab increases, physicians dealing with such patients must be aware of their clinical manifestations so that an accurate diagnosis can be made and adequate therapy can be instituted. The decision about continuing or suspending biological therapy must be individualized and based on the response to the antipsoriatic approach (standard therapy), psoriasis severity, possibility of using alternative therapeutic forms for IBD and potential deleterious effect on IBD.

ACKNOWLEDGEMENTS

The authors thank the editorial suggestions by Dr. Ricardo Romiti and by Dr. Flavio Steinwurz concerning this manuscript.
